Blinklab Limited · ASX:BB1
Blinklab — Investor Presentation (November 2024)
24 slides from Blinklab's investor presentation, Nov 20, 2024
Slide 1: Early and accurate diagnosis of autism and ADHD
For personal use only Early and accurate diagnosis of autism and ADHD Introducing a breakthrough AI-powered smartphone platform for neurological testing BlinkLab Ltd (ASX:BB1), November 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background For personal use only information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 3: What is autism?
What is autism? For personal use only ● “Neurodevelopmental condition that affects how the brain processes sensory information.” ● Autism impacts: ○ Social development ○ Language development ○ Sensory processing ○ Behavior and interests
Slide 4: Economic burden of autism in US: $700B in 2024
Economic burden of autism in US: $700B in 2024 ”The economic burden is significant and alarming” 1 For personal use only • Prevalence has grown up to 2-4% among children2 • Autism healthcare expenses are soaring3 • USA: Costs for an autism diagnostic evaluation: $1,000 to $5,000 • USA: Lifetime cost
Slide 5: The challenge: No medical test available for autism
The challenge: No medical test available for autism Governments and healthcare providers are on the lookout for disruptive technologies For personal use only Sources: Left up - The Australian 14 February 2024; Left down - Sydney University 6 February 2023, www.sydney.edu.au/brain-mind; Right up - Na
Slide 6: Autism diagnosis is expensive, inefficient, and often late
Autism diagnosis is expensive, inefficient, and often late The costly labor and time intensive diagnostic evaluations are unnecessary for many children. For personal use only Parental Autism Autism Diagnosis at Late observations screening diagnostic evaluation age 5-6 intervention Concerns arise By
Slide 7: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis Efficient screening leads to better allocation of resources throughout the diagnostic workflow For personal use only Parental BlinkLab Diagnostic Diagnosis at Early and personalized intervention observations screening evaluation age 2-3 and a
Slide 8: For personal use only
For personal use only
Slide 9: Our patented solution: Neuroscience on a smartphone
Our patented solution: Neuroscience on a smartphone Minuscule facial reflexes, evoked by our app, For personal use only generate a digital biomarker for autism. Evokes facial reflexes By presenting visual and auditory stimuli during smartphone use. Computer vision Facial features are tracked on the
Slide 10: Large-Scale Study Validates and Enhances BlinkLab's Accuracy in Detecting Autism
Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children For personal use only News announcement 19 November 2024 In a sample of 441 children, BlinkLab achieved a sensitivity of 91% and specificity of 85%
Slide 11: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 12: BlinkLab App and Online Portal are fully developed
BlinkLab App and Online Portal are fully developed Validated in >8,000 subjects tested globally, including people with limited access to healthcare. For personal use only ● Remote testing Enables accessible and global diagnostics. ● Scalable solution Easily adaptable for clinical and diverse researc
Slide 13: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions Since our product launched in 2022, we have established global partnerships academic and clinical institutes. 2022 2023 2024 ongoing For personal use only Proof-of-concept of smartphone-based Princeton University neurometric evaluations. Mult
Slide 14: BlinkLab to Participate in the Monash University MAGNET Project
BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project For personal use only News announcement 13 November 2024 • The MAGNET project is an ongoing large cohort study aiming to enroll 1,000 families with children diagnosed with autism, ADHD, or both autism and ADHD. • MA
Slide 15: BlinkLab outperforms FDA-approved digital peers
BlinkLab outperforms FDA-approved digital peers We are leaders in the rapidly growing space of digital diagnostics and therapeutics. For personal use only Sensitivity 91% 52%* 71% Specificity 85% 19%* 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k) * Calculated ov
Slide 16: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models.
Slide 17: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 18: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 19: Optimizing AI and machine learning for BlinkLab Dx
Optimizing AI and machine learning for BlinkLab Dx Establishing academic partnerships is crucial not only for academic and clinical adoption, but also for training our ML models with diverse datasets that reflect real-world data. For personal use only PREVIOUS STUDIES CURRENT WORK Our binary AI clas
Slide 20: R&D Pipeline
R&D Pipeline Our R&D pipeline is focused on obtaining FDA 510(k) clearance and EU regulatory approval for BlinkLab as a diagnostic adjunct for autism and ADHD. For personal use only Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory a
Slide 21: Important milestones
Important milestones News pipeline: Updates on regulatory studies on autism and ADHD and new partnerships For personal use only Milestone Timeframe Start of activities for FDA registrational study in autism *2Q 2024 Interim data from ADHD clinical study in EU *3Q 2024 Appointment of US based CRO to
Slide 22: Capital structure of ASX:BB1
Capital structure of ASX:BB1 Pre-IPO Overview (November 2021 – March 2024) For personal use only November 2021: Seed Raising of A$1.2M A$0.07 November 2023: Pre-IPO Raising of A$1.4M A$0.12 April 2024: IPO Raising of A$7.0M A$0.20 Public Market Overview (19 November 2024) Share Price A$0.31 Shares o
Slide 23: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p
Slide 24: For further information please contact
ASX:BB1 For personal use only For further information please contact: Henk-Jan Boele (MD, PhD) Brian Leedman Chief Executive Officer Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M: +61 (0) 412 281 780 www.blinklab.org | info@blinklab.org | BLINKLAB LIMITED |